CD8A and neoplasm: These findings are consistent with previous evidence suggesting that intratumor bacterial therapy can delay tumor growth but may be insufficient to control the rapid outgrowth of the tumor periphery.49 However, our results demonstrate that the addition of OT-I CD8 T cells to the E. coli therapy significantly enhances its efficacy, resulting in a more comprehensive and effective tumor regression.